SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
22.15
-0.65 (-2.85%)
Jan 21, 2026, 11:19 AM CET
111.15%
Market Cap1.22B
Revenue (ttm)n/a
Net Income (ttm)-106.28M
Shares Out53.33M
EPS (ttm)-2.21
PE Ration/a
Forward PE84.73
Dividendn/a
Ex-Dividend Daten/a
Volume33,490
Average Volume141,481
Open22.85
Previous Close22.80
Day's Range22.05 - 23.05
52-Week Range10.47 - 25.30
Beta1.05
RSI53.56
Earnings DateFeb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.